At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Denosumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone
In Brief
A Phase 2 clinical trial evaluating Denosumab and Calcium/Vitamin D for GCT and Giant Cell Tumor of Bone. Completed, enrolled 37 participants.
Detailed Summary
To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGCT, Giant Cell Tumor of Bone
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedNov 2006
Primary CompletionApr 2008
Study CompletionFeb 2011
TodayJul 2026
First PostedNov 6, 2006
Enrollment StartJul 10, 2006
Primary CompletionApr 7, 2008
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.7 years ago
Interventions
Denosumabbiological
Administered by subcutaneous injection
Calcium/Vitamin Ddietary